SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

Schriftzug "News" (Symbolbild). pixabay.com

PR Newswire

NEW YORK, June 18, 2019

NEW YORK, June 18, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Array BioPharma ("Array" or the "Company") (NASDAQ: ARRY) in connection with the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE:PFE). Under the terms of the agreement, Array shareholders will receive $48 per share in cash for each ARRY share they own.

If you are a shareholder of Array who wishes to discuss the investigation or have any questions about this notice and your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY 10036
(212) 682-3025
(888)593-4771
stockinfo@weisslawllp.com

Or visit our website
http://www.weisslawllp.com/array-biopharma/

Or follow us on Twitter @MarketsAlert

WeissLaw LLP (PRNewsfoto/WeissLaw LLP)

WeissLaw is investigating whether Array's Board acted to maximize shareholder value prior to entering into the agreement. Notably, the acquisition is a strategic transaction which Pfizer hopes to leverage ARRY's wide range of targeted cancer medicines to propel it as an industry leader. According to Albert Bourla, Pfizer's CEO, the deal will strengthen Pfizer's "innovative biopharmaceutical business, is expected to enhance its long-term growth trajectory, and sets the stage to create a potentially industry leading franchise for colorectal cancer." The deal will also expand Pfizer portfolio to include multiple high-potential investigational therapies and numerous royalty-generating out-licensed medicines.

ARIVA.DE Börsen-Geflüster

Kurse

Array BioPharma

0,00%

Pfizer Inc.

26,27 $

0,00%

Finally, the Company recently announced positive financial results, reporting robust US demand for its marquee products with over $35 million in net sales, and a more than 200% increase in ARRY's share price since January.

WeissLaw is also concerned whether the deal creates shareholder value for Array's shareholder. Specifically, WeissLaw is investigating whether Array's Board conducted a fair process in agreeing to the proposed merger, whether the proposed merger undervalues the Company, and whether all material information related to the proposed merger is fully and fairly disclosed.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-array-biopharma-acquisition-300870849.html

SOURCE WeissLaw LLP

Mehr Nachrichten zur Pfizer Inc. Aktie kostenlos abonnieren

E-Mail-Adresse

Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.